Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 116 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CF Control Clear all
Completed Phase 4 Interventional Results available

Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)

NCT02677701
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
azithromycin, placebo (for azithromycin), inhaled tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
39
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 3 Interventional Results available

A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

NCT01187407
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
LY2216684, Placebo, SSRI
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chino, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 23, 2026, 5:53 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Regional Phenotyping of CF and Non-CF Bronchiectasis

NCT04793867
View directory record Official record
Conditions
Cystic Fibrosis, Non-CF Bronchiectasis
Interventions
Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 3 Interventional

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

NCT02104245
View directory record Official record
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin dispersion for inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Long Term Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 2

NCT02447783
View directory record Official record
Conditions
Healthy
Interventions
Control Capsules, Mars Cocoa Extract Capsules
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
30 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

NCT02514473
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-809, Placebo, VX-770
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Not applicable Interventional

Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience

NCT01013896
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Motivational Interviewing, Cystic Fibrosis Education
Behavioral · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
16 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily Insulin

NCT03804983
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Hybrid Closed Loop (HCL), Control-IQ with MyTDI
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 18 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 23, 2026, 5:53 PM EDT
Active, not recruiting No phase listed Observational

Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI

NCT02848560
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Hyperpolarized Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 12 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 23, 2026, 5:53 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia

NCT07284290
View directory record Official record
Conditions
Dementia With Lewy Bodies, Parkinson Disease Dementia, Healthy Controls
Interventions
Syn-One skin biopsy, Multi modal MRI, Assessment of dynamic EEG features over 48-hour periods across all study aims, Plasma biomarkers, Galantamine HBr extended-release 8mg capsules (8mg ER).
Procedure · Diagnostic Test · Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
50 Years to 89 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Cystic Fibrosis (CF) Subjects

NCT00928135
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Xylitol, Hypertonic saline
Drug
Lead sponsor
Joseph Zabner
Other
Eligibility
12 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Results available

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

NCT01225211
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lumacaftor, Ivacaftor, Lumacaftor Placebo, Ivacaftor Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
38
States / cities
Birmingham, Alabama • Anchorage, Alaska • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 23, 2026, 5:53 PM EDT
Terminated Phase 3 Interventional

Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects

NCT00125346
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tobramycin Inhalation Powder
Drug
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 21 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
26
States / cities
Mobile, Alabama • Phoenix, Arizona • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 3 Interventional Results available

A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

NCT03525548
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-445/TEZ/IVA, TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
28
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Not applicable Interventional

Effects of a Partially Supervised Conditioning Program in CF

NCT01744561
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Exercise Intervention
Behavioral
Lead sponsor
Wuerzburg University Hospital
Other
Eligibility
12 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 23, 2026, 5:53 PM EDT
Active, not recruiting Not applicable Interventional

Lung Transplant READY CF 2: A Multi-site RCT

NCT06030206
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Investigator-designed lung transplant education resource (Research Intervention), Publicly available transplant education resource (Attention-control)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 23, 2026, 5:53 PM EDT
Terminated Early Phase 1 Interventional

19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation

NCT03497117
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lung Clearance Index, MRI with PFP
Device · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Not applicable Interventional Results available

Behavioral & Nutritional Treatment to Help CF Preschoolers Grow

NCT00241969
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Cystic Fibrosis
Interventions
Behavioral and Nutrition Treatment, Education and Attention Control
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 6 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
5
States / cities
Tucson, Arizona • Ann Arbor, Michigan • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 1Phase 2 Interventional

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

NCT06016088
View directory record Official record
Conditions
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
Interventions
RSP-1502, Tobramycin inhalation solution
Drug
Lead sponsor
Respirion Pharmaceuticals Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 23, 2026, 5:53 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

NCT04550260
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Durvalumab, Placebo, cisplatin + fluorouracil, cisplatin + capecitabine, Radiation
Drug · Radiation
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Louisville, Kentucky • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 2 Interventional

Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation

NCT02589236
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Cavosonstat, Placebo
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
46
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 23, 2026, 5:53 PM EDT
Completed No phase listed Observational

Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy

NCT01858519
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 99 Years
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
47
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Long Beach, California + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 23, 2026, 5:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

CF And Effects of Drugs Mixed Ex Vivo With Sputum for Mucolytic Treatment

NCT01533636
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)

NCT03150719
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tezacaftor/Ivacaftor, Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 23, 2026, 5:53 PM EDT